CSGH yields 20000000.00% · ABBV yields 3.06%● Live data
📍 CSGH pulled ahead of the other in Year 1
Combined, CSGH + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CSGH + ABBV for your $10,000?
China Sun Group High-Tech Co., through its subsidiary, Dalian Xinyang High-Tech Development Co. Ltd., engages in the production and sale of cobaltosic oxide and lithium cobalt oxide used in lithium ion rechargeable batteries in the People's Republic of China and internationally. It provides battery level cobaltosic oxide, a cathode material used in the manufacturing of lithium cobalt oxide; and lithium iron phosphate, a cathode material used in lithium iron phosphate batteries. The company also offers ternary cathode material, which is applied as the main cathodes of small-sized communication and power instruments, such as portable power tools, electronic apparatus, laptops, and video cameras, as well as electric autos and bicycles. It serves lithium ion battery manufacturers, end product users, and lithium series product manufacturers. The company was formerly known as Capital Resource Funding, Inc. and changed its name to China Sun Group High-Tech Co. in August 2007. China Sun Group High-Tech Co. is headquartered in Dalian, the People's Republic of China.
Full CSGH Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.